UCHealth Anschutz Cancer Pavilion in Aurora is now employing a groundbreaking technology that significantly enhances the ability of surgeons to detect and remove cancer cells that might otherwise be missed. This innovative approach promises to improve patient outcomes and increase confidence in achieving complete cancer removal during surgical procedures.
Key Takeaways
- A new fluorescent dye, Pafolacianine (CYTALUX), helps surgeons visualize cancer cells.
- The technology has been approved by the FDA for use in lung and ovarian cancers.
- It aids in identifying cancers missed by traditional imaging and the naked eye.
- UCHealth was the first in Colorado to use this on adult lungs.
Illuminating Cancer Cells
Surgeons at UCHealth are utilizing Pafolacianine, also known by its brand name CYTALUX, a specialized molecule designed to bind to cancer cells. Once administered to patients via infusion hours before surgery, the molecule causes these cancerous cells to emit a fluorescent glow when exposed to a near-infrared light. This visual cue allows surgical teams to more accurately identify and target malignant tissues.
Enhanced Surgical Precision
Dr. Robert Meguid, a specialist in thoracic surgery at UCHealth, highlighted the transformative impact of this technology. "This is, to me, a really exciting time in healthcare," Dr. Meguid stated. "Because there’s so many advances that are making it to patient care delivery that are improving their outcomes, to help patients be cancer free or have improved quality of life."
The technology is particularly beneficial for detecting metastatic cancers that have spread to the lungs from other parts of the body, which can be challenging to identify through CT scans or visual inspection alone. By making these previously undetectable cells visible, Pafolacianine provides surgeons with greater assurance that all cancerous tissue has been excised, thereby minimizing the risk of recurrence.
A Leading Edge in Cancer Care
UCHealth Anschutz Cancer Pavilion has been at the forefront of adopting this advanced technique, using it for approximately 18 months. They were the first medical center in Colorado to implement Pafolacianine for adult lung cancer surgeries. While still not widely adopted nationally, the technology is gaining momentum, signaling a significant step forward in surgical oncology and patient care.
